Armata Pharmaceuticals FY2025 EPS Boosted by HC Wainwright

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Equities researchers at HC Wainwright increased their FY2025 EPS estimates for Armata Pharmaceuticals in a report issued on Thursday, January 29th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.15) per share for the year, up from their prior estimate of ($1.46). The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2025 earnings at ($0.19) EPS.

Separately, Jones Trading initiated coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They issued a “buy” rating and a $15.00 price target for the company. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $12.00.

Armata Pharmaceuticals Stock Performance

Shares of ARMP stock opened at $6.70 on Monday. Armata Pharmaceuticals has a fifty-two week low of $0.90 and a fifty-two week high of $16.34. The firm has a market cap of $243.95 million, a P/E ratio of -4.14 and a beta of 1.42. The business’s 50 day moving average price is $6.31 and its 200-day moving average price is $4.57.

Hedge Funds Weigh In On Armata Pharmaceuticals

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC lifted its stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 17.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,988 shares of the company’s stock after purchasing an additional 6,034 shares during the quarter. SeaCrest Wealth Management LLC owned about 0.11% of Armata Pharmaceuticals worth $274,000 as of its most recent filing with the Securities & Exchange Commission. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.